MedTrace Logo

Evaluation of FPT-20 for the Treatment of Spermatogenesis and Semen Disorders

NCT05399212 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-06-08

No results posted yet for this study

Summary

This clinical study aims to evaluate the efficacy and safety of a novel, natural-derived formulation (FPT-20) in supporting spermatogenesis. The investigation focuses on the formulation's potential to reduce inflammatory processes and support tissue regeneration within the testicular lobules, seminiferous tubule epithelium, and surrounding connective tissues. Additionally, the study assesses its ability to restore Leydig and Sertoli cell functions in patients with spermatogenic failure secondary to testicular inflammation.

Conditions

  • Spermatogenesis and Semen Disorders
  • Infertility, Male

Interventions

DRUG

FPT-20

Participants receive FPT-20 orally at a standardized dosage of 1 tablet once daily. The intervention is administered continuously for a duration of 6 to 12 months to ensure sufficient exposure for the evaluation of therapeutic efficacy on spermatogenesis.

Sponsors & Collaborators

  • Trieu, Nguyen Thi, M.D.

    lead INDIV

Principal Investigators

  • Nguyen Thi Trieu, Dr. · Trieu, Nguyen Thi, M.D.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-29
Primary Completion
2026-05-20
Completion
2026-05-20

Countries

  • Vietnam

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05399212 on ClinicalTrials.gov